Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer
2024

Trends in Antiandrogen Receptor Inhibitor Use and Costs in Prostate Cancer

publication Evidence: moderate

Author Information

Author(s): Hikari Miura, Hayato Yamamoto, Yoshiharu Okuyama, Noritaka Ishi, Ryuma Tanaka, Takuya Oishi, Fumiya Yoneyama, Tomoko Hamaya, Kyo Togashi, Naoki Fujita, Teppei Okamoto, Chikara Ohyama, Shingo Hatakeyama

Primary Institution: Department of Urology, Hirosaki University School of Medicine, Hirosaki, Japan

Hypothesis

We aimed to examine trends in novel antiandrogen receptor signal inhibitor (ARSI) usage and medical costs.

Conclusion

ARSI usage and medical costs associated with prostate cancer increased significantly from 2016 to 2021.

Supporting Evidence

  • The usage of ARSI increased from 6.1% in 2016 to 16% in 2021.
  • Medical costs for prostate cancer-specific agents increased 1.8-fold from 2016 to 2021.
  • Despite limited ARSI usage, they accounted for a significant portion of prostate cancer medication costs.

Takeaway

Doctors are using more new medicines for prostate cancer, which are getting more expensive over time.

Methodology

Data from The National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) was analyzed for outpatient prescriptions from 2016 to 2021.

Potential Biases

The analysis was limited to data from Japan, which may not be generalizable to other countries.

Limitations

The study lacked individual patient data and could not distinguish between metastatic castration-sensitive and castration-resistant prostate cancer.

Participant Demographics

The study included patients with prostate cancer, with a noted increase in ARSI usage among older patients.

Statistical Information

P-Value

<0.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1002/cam4.70226

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication